Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Hall Laurie J Trustee

Hall Laurie J Trustee reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.7% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,422 shares of the medical research company’s stock after selling 25 shares during the period. Hall Laurie J Trustee’s holdings in Thermo Fisher Scientific were worth $740,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of TMO. Intech Investment Management LLC lifted its stake in shares of Thermo Fisher Scientific by 19.4% in the 2nd quarter. Intech Investment Management LLC now owns 3,142 shares of the medical research company’s stock valued at $1,738,000 after purchasing an additional 510 shares during the period. Pacer Advisors Inc. raised its position in shares of Thermo Fisher Scientific by 6.2% in the second quarter. Pacer Advisors Inc. now owns 28,900 shares of the medical research company’s stock worth $15,982,000 after acquiring an additional 1,685 shares during the period. Thrivent Financial for Lutherans grew its position in shares of Thermo Fisher Scientific by 5.5% during the 2nd quarter. Thrivent Financial for Lutherans now owns 119,619 shares of the medical research company’s stock valued at $66,148,000 after acquiring an additional 6,185 shares during the period. Summit Trail Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 3.9% in the 2nd quarter. Summit Trail Advisors LLC now owns 4,164 shares of the medical research company’s stock valued at $2,304,000 after purchasing an additional 157 shares in the last quarter. Finally, Westwood Holdings Group Inc. boosted its position in Thermo Fisher Scientific by 80.5% during the second quarter. Westwood Holdings Group Inc. now owns 2,226 shares of the medical research company’s stock worth $1,231,000 after purchasing an additional 993 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on TMO shares. Stifel Nicolaus reduced their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Scotiabank began coverage on shares of Thermo Fisher Scientific in a report on Monday, December 23rd. They set a “sector perform” rating and a $605.00 price objective on the stock. Bank of America cut their target price on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Barclays lowered their price objective on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Finally, Robert W. Baird decreased their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Four analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $648.95.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the transaction, the senior vice president now owns 12,736 shares of the company’s stock, valued at $7,134,197.76. This trade represents a 13.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the sale, the chief executive officer now owns 111,192 shares in the company, valued at approximately $58,960,669.92. The trade was a 8.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,150 shares of company stock worth $25,954,465 over the last ninety days. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.4 %

TMO stock opened at $559.72 on Monday. The firm has a market cap of $214.09 billion, a PE ratio of 35.09, a PEG ratio of 3.59 and a beta of 0.76. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The firm’s 50 day moving average price is $529.96 and its 200-day moving average price is $568.33.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company’s quarterly revenue was up .2% on a year-over-year basis. During the same period last year, the company earned $5.69 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were issued a $0.39 dividend. The ex-dividend date was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific announced that its board has authorized a share buyback program on Friday, November 15th that permits the company to buyback $4.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase up to 2% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its shares are undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.